

GRIFOLS, S.A.

AUDIT COMMITTEE

REPORT ON RELATED PARTY TRANSACTIONS 2022

The Audit Committee of Grifols, S.A. (the "**Company**") has prepared this annual report on related party transactions (the "**Report**"), in accordance with the Good Governance Code of Listed Companies. It includes the Company's related party transactions carried out between 1 January and 31 December of 2022.

On 18 February 2015 the Board of the CNMV approved the Good Governance Code of Listed Companies, which has been updated in June 2020. The recommendation 6 sets out that:

"Listed companies drawing up the following reports on a voluntary or compulsory basis should publish them on their website well in advance of the annual general shareholders' meeting, even if their distribution is not mandatory:

- a) *Report on auditor independence.*
- b) *Reports of the operation of the audit committee and the nomination and remuneration committee.*
- c) *Audit committee report on related party transactions."*

Pursuant to said recommendation, this Report shall be published on the Company's website well in advance of the Company's 2023 Ordinary General Shareholders' Meeting. Also, the information detailed in this Report is available to the shareholders of the Company in the Company's annual accounts and in its annual corporate governance report for financial year 2022.

During the financial year 2022, the main transactions carried out by the Company with other companies of the Group have been the following:

Corporate name of the group' subsidiary	Brief description of the transaction	Amount (in thousands of euros)
Fundación Privada Victor Grifols i Lucas	Expenses for management or collaboration agreements	450
Probitas Fundación Privada	Expenses for management or collaboration agreements	3,383
Access Biologicals LLC	Sales	5,269
Access Biologicals LLC	Purchases	9

Access Biologicals LLC	Operating expenses	34
Access Biologicals LLC	Dividends	3,728
Shanghai Raas Blood Products Co. Ltd.	Dividends	6,989
Shanghai Raas Blood Products Co. Ltd.	Sales	262
Grifols Egypt for Plasma Derivatives (S.A.E.)	Sales	8,172
Anhui Tonrol Pharmaceutical Co.	Sales	319,669
Bio Darou P.J.S. Co.	Sales	5,798

In accordance with the applicable law, the transactions considered significant as a result of its amount or nature, which have been carried out between the Company, or a subsidiary, with other related parties which are considered related parties pursuant to the international accounting standards adopted by the EU, are detailed below:

Company name of the related party	Brief description of the transaction	Amount (in thousands of euros)
Scranton Enterprises, B.V.	These are payments for right-of-use assets between Centuri3n Real Estate S.A.U. and Grifols, S.A., where Scranton Enterprises B.V. (a significant shareholder of Grifols, S.A.) is the sole shareholder of Centuri3n Real Estate S.A.U.	6,300
Scranton Enterprises, B.V.	This consists of sales revenue from the execution of a delegated construction contract between Grifols, S.A. and Centuri3n Real Estate S.A.U., where Scranton Enterprises B.V. (a significant shareholder of Grifols, S.A.) is the sole shareholder of Centuri3n Real Estate S.A.U.	3,464

Scranton Enterprises, B.V.	This consists of expenses for services related to an advertising contract between Grifols, S.A. and Club Joventut Badalona, S.A.D., where Scranton Enterprises B.V. (a significant shareholder of Grifols, S.A.) is the sole shareholder of Club Joventut Badalona, S.A.D.	341
Scranton Enterprises, B.V.	This consists of expenses for several purchases between Grifols, S.A. and Juve & Camps, S.A., where Scranton Enterprises B.V. (a significant shareholder of Grifols, S.A.) is the significant shareholder of Juve & Camps, S.A.	169

Barcelona, 20 February 2023
Audit Committee